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Healthcare workers (HCWs) are at increased risk of exposure to
respiratory pathogens and may transmit infection to vulnerable
patients. This study summarises a recent systematic review, which
aimed to assess evidence that influenza or pneumococcal
vaccination of HCWs provides indirect protection for those patients
most at risk of severe or complicated acute respiratory infection. A
number of healthcare databases and sources of grey literature were
searched using a predefined strategy, and citations screened for
eligibility in accordance with specified inclusion criteria. Risk of bias
was assessed using validated tools and results summarised
qualitatively. Twenty papers were included in the final review, all of
which considered influenza vaccination of HCW. As such, planned
subanalysis of pneumococcal vaccination was discarded. The
majority of primary research studies included (11/14) were
conducted in long-term care facilities, but there was marked
heterogeneity in terms of the population, intervention/exposure and
outcomes considered. Consistency in the direction of effect was
observed across several different outcome measures, suggesting that
influenza vaccination of HCWs is likely to offer some protection.
Further evidence is, however, required from acute care settings.
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Introduction
Respiratory pathogens cause significant morbidity and mor-
tality, particularly amongst those vulnerable to severe or
complicated infection. Evidence-based strategies for the
prevention and control of respiratory infection are therefore
essential. Healthcare workers are likely to be at increased risk
of exposure and may transmit respiratory infections to their
patients through the very nature of their work. Indeed, a
number of outbreaks of respiratory illness have been
described in healthcare settings,1–10 often involving health-
care workers. Both influenza and pneumococcal infections
are important causes of acute respiratory disease and are
vaccine preventable. Whilst there is generally considered to
be insufficient evidence for the routine use of pneumococcal
vaccine amongst healthcare workers, influenza vaccination
has been widely recommended.11,12 Despite efforts to
encourage influenza vaccination, however, coverage has been
historically poor and ethical arguments for mandatory
vaccination have been raised, focusing not only on direct
protection for workers themselves, but indirect protection
for those they care for. To date, evidence for the indirect
protection of vulnerable groups following either influenza or
pneumococcal vaccination of healthcare workers has been
uncertain. The following article summarises a recently
published systematic review that addresses this issue. The
primary manuscript can be accessed for further detail
through the following citation: ‘Dolan et al. Vaccination of
HealthCare Workers to Protect Patients at Increased Risk for
Acute Respiratory Disease. EID 2012;18(8):1225–1234.’
Methods
Multiple electronic healthcare databases, sources of evidence-
based reviews, guidelines and grey literature were searched
using a pre-defined, peer-reviewed search strategy. A three-
stage process was used to assess eligibility for inclusion,
screening citations first by title, then abstract and then full
text. Inclusion criteria considered appropriate study design,
subject population (patients of all ages at higher risk of severe
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or complicated illness as a result of acute respiratory
infection), intervention (influenza or pneumococcal vacci-
nation of any person providing health care to higher risk
groups), and outcomes (cases or consultations, death or
hospitalisation for acute respiratory disease, influenza,
influenza-like-illness (ILI) or pneumococcal disease). A
number of validated tools were used to assess the risk of
bias at outcome level, and data were synthesised qualitatively
using a narrative approach.
Results
A total of 12 352 citations were identified (10 713 from
healthcare databases and the remainder from additional
sources). No articles considering pneumococcal vaccination
were identified, but twenty studies addressing the effect of
influenza vaccination of healthcare workers met the inclusion
criteria. Fourteen (70%) of the 20 studies were primary
research articles (four randomised controlled trials and ten
observational studies) and six different reports of two pre-
existing systematic reviews. There was marked heterogeneity
in the populations, interventions/exposures and outcomes
considered. The majority (11/14) of the primary research
papers were conducted in long-term residential care settings
with the remainder conducted in a renal dialysis facility (1
study);13 a paediatric hospital (1 study);14 and an adult
oncology hospital (1 study).15 All identified studies were
judged to be at some risk of bias. Table 1 summarises the
qualitative synthesis of evidence for each specified outcome
measure.
Conclusion
Since no articles considering pneumococcal vaccination of
healthcare workers were identified, findings from this
review were restricted to influenza vaccination only. They
highlight that evidence for the effectiveness of influenza
vaccination of healthcare workers in providing indirect
protection for vulnerable groups is limited. Studies were
primarily conducted amongst long-term residential care
settings, thus presenting challenges for direct extrapolation
of the findings to other at risk groups, and to short-stay
acute care settings. Two previous systematic reviews23,28
indicate that influenza vaccination of healthcare workers
might be effective in reducing death and ILI amongst
residents of elderly care homes, but the authors concluded
that evidence was lacking and confined to non-specific
outcome measures. This review considers additional obser-
vational data and indicates in general, a uniform direction
of effect across multiple outcome measures, suggesting that
influenza vaccination of healthcare workers is likely to
offer some protection to vulnerable patients. Whilst this
provides further evidence to support current recommen-
dations for vaccinating healthcare workers against influ-
enza, it should be considered alongside ethical arguments
(particularly the balance between autonomy and non-
maleficence) when formulating policy decisions. Future
well-designed studies that strengthen the existing evidence
base (especially amongst other at risk groups and in acute
care settings) might, however, encourage compliance with
guidelines and result in improved uptake. Studies con-
cerning the effect of pneumococcal vaccine should also be
considered. In practice, both influenza and pneumococcal
vaccination should be seen as important elements of a
broad package of infection prevention and control mea-
sures including good hand and respiratory hygiene,
environmental cleaning, protection against respiratory
droplets and cohorted care during outbreaks.29,30
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Table 1. Summary of findings by outcome measure
Outcome Evidence available Narrative synthesis
Acute respiratory disease Statistical estimates from one randomised
controlled trial16 providing two different
measures of effect (clinical episodes of
viral illness/lower respiratory tract infection).
Inconsistent effect but uniform in direction, suggesting
possible protection. Difficult to ascertain whether this
may be attributable to influenza infection due to the
non-specific nature of the measures used.
Clinically defined cases of
influenza-like-illness (ILI)
Statistical estimates of clinically defined ILI
from three randomised controlled trials16–18
and two prospective cohort studies.19,20
Additional statistical estimate of cases of
influenza from one cross-sectional study21
and observational data from two further
studies providing no statistical estimates.13,22
Pooled data23 from the three randomised controlled trials
suggest a statistically significant protective effect when
adjusted for clustering. This is supported by observational
data, of which two of the five remaining studies also
demonstrate statistically significant reductions in
risk,19,20 although noted to be at higher risk of bias.
GP consultations for ILI Statistical estimate from one randomised
controlled trial.18
Inconsistent effect across different seasons. Small,
statistically significant reduction in the rate of
consultations for one season only, although overall
statistically significant, protective effect when converted
to an adjusted odds ratio.23
Outbreaks/clusters of ILI Statistical estimates from three observational
studies.20,24,25
All three studies demonstrate statistically significant,
protective effects, although different ILI definitions employed,
imprecise estimates and a high risk of bias.
Laboratory diagnosed
influenza
Statistical estimates from one randomised
controlled trial26 and two observational
studies.14,15 Observational data, with no
statistical analysis from a further randomised
controlled trial.16
Pooled data from the two RCTs23 suggest a small non-
significant protective effect. Direction of effect supported
by data from two additional observation studies14,15 which
demonstrate statistically significant protective effects.
Notable risk of bias and imprecision due to very small
sample sizes.
Laboratory confirmed
outbreaks of influenza
Statistical estimate from one observational
study.27
No statistically significant difference although vaccination
coverage appeared higher in homes experiencing outbreaks.
Analyses are, however, unadjusted and imprecise due to
small numbers.
Respiratory mortality Statistical estimates from four randomised
controlled trials16–18,26 although each provides
a different measure (deaths associated with
pneumonia,16 respiratory deaths,17 deaths with
ILI18 and laboratory diagnosed influenza
at death.26)
Pooled estimates23 using data for deaths associated with
pneumonia16 and respiratory deaths17 suggest a small,
non-significant protective effect. Small non-significant
protective effects for mortality following ILI18 and mortality
due to laboratory confirmed influenza26 are also demonstrated
in individual studies.
All-cause mortality Statistical estimate from four randomised
controlled trials.16–18,26
Inconsistent effect, but uniform in direction. Pooled data23
suggest a statistically significant, protective effect when
adjusted for clustering.
Hospitalisation Statistical estimates from two randomised
controlled trials17,18 providing three different
measures of effect (hospitalisation,17,18
hospitalisation for respiratory causes17 and
admission with ILI.18)
No clear effect demonstrated.
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